GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4SC AG (LTS:0R6U) » Definitions » Institutional Ownership

4SC AG (LTS:0R6U) Institutional Ownership : 0.28% (As of Jun. 05, 2024)


View and export this data going back to 2011. Start your Free Trial

What is 4SC AG Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, 4SC AG's institutional ownership is 0.28%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, 4SC AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, 4SC AG's Float Percentage Of Total Shares Outstanding is 0.00%.


4SC AG Institutional Ownership Historical Data

The historical data trend for 4SC AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4SC AG Institutional Ownership Chart

4SC AG Historical Data

The historical data trend for 4SC AG can be seen below:

2020-05-31 2020-06-30 2020-07-31 2020-08-31 2020-09-30 2020-10-31 2020-11-30 2020-12-31 2021-01-31 2021-02-28
Institutional Ownership 0.59 0.41 0.41 0.41 0.31 0.31 0.31 0.28 0.28 0.28

4SC AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


4SC AG (LTS:0R6U) Business Description

Industry
Traded in Other Exchanges
Address
Fraunhoferstraße 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. It Geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.

4SC AG (LTS:0R6U) Headlines

No Headlines